GlycoMimetics, Inc. GLYC
Jul 2, 2025, 3:58 PM EDT
52-week range unavailable
- YTD
- -36.93%
- 1 year
- -41.94%
- Market cap
- 13.96M
- Revenue (ttm)
- 10.00K
- Shares out
- 64.48M
- Forward P/E
- -2.41
- YTD return
- -36.93%
- 1-year return
- -41.94%
- Volume
- 612
- Open
- 16.25
- Previous close
- 15.71
- Day's range
- 15.52 – 17.39
- Beta
- 1.84
- Price target
- 1.00 (-93.6%)
- Earnings date
- Oct 2, 2024
Key statistics
- Enterprise value
- 3.82M
- PEG ratio
- 0.00
- Price / sales
- 1396.08
- Price / book
- 0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -22.15M
- Total cash
- 22.39M
- Total debt
- 448.77K
- Return on equity
- -104.49%
- Short % of float
- 12.61%
- 50-day average
- 0.2958
- 200-day average
- 0.6851
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 2, 2024
Expected Oct 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.15 | — | — |
| Oct 2, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.16 | -0.17 | -0.01 | -6.25% |
| Mar 27, 2024 | Dec 1, 2023 | -0.15 | -0.14 | +0.01 | +6.67% |
| Nov 3, 2023 | Sep 1, 2023 | -0.14 | -0.14 | 0.00 | 0.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.18 | -0.13 | +0.05 | +27.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 26, 2024 | TD Cowen | down | Buy | Hold |
| Jun 4, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 6, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 22, 2023 | Capital One | init | — | Overweight |
| Aug 3, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- glycomimetics.com
News
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
12 Health Care Stocks Moving In Thursday's After-Market Session 
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals 
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference 
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC 
Crescent Biopharma Appoints David Lubner to Board of Directors 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
Your note
Sign in to keep a note on GLYC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS PATRICIA S | Director | Stock Award(Grant) | Dec 28, 2023 | 58,608 |
| GOLDBERG MARK ALAN | Director | Stock Award(Grant) | Mar 27, 2024 | 36,325 |
| HAHN BRIAN M | Chief Financial Officer | Purchase | Jun 17, 2024 | 70,643 |
| INVUS PUBLIC EQUITIES ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 29, 2024 | 0 |
| JOHNSON BRUCE S | Officer | Purchase | May 7, 2023 | 138,980 |
| JUNIUS DANIEL M | Director | Stock Award(Grant) | Mar 27, 2024 | 98,459 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 14.80% | 9,544,262 | 2.07M | Sep 29, 2024 |
| Vanguard Group Inc | 4.14% | 2,670,208 | 578.10K | Sep 29, 2024 |
| Siren, L.L.C. | 3.05% | 1,965,114 | 425.45K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.21% | 781,100 | 169.11K | Sep 29, 2024 |
| Blackrock Inc. | 1.13% | 727,858 | 157.58K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 521,223 | 112.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 1,925,297 | 416.83K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.13% | 730,599 | 158.17K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 297,994 | 64.52K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 112,959 | 24.45K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 80,838 | 17.50K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 64,457 | 13.95K | Oct 30, 2024 |